Funding for this research was provided by:
Novo Nordisk Fonden (NNF20SA0062834)
Received: 7 May 2020
Accepted: 14 May 2020
First Online: 10 June 2020
Ethics approval and consent to participate
: The study has been approved by the Danish Committee on Health Research Ethics on April 3, 2020 with ref. no. H-20022574 (for protocol amendment report no. 73409). The study will ensure the protection of human participants according to the Helsinki Declaration and in accordance with Good Clinical Practice Guidelines. Participants (hospital admitted COVID-19 patients) will give written informed consent to participate. A completed patient informed consent form is required from all participants in the study and must be signed by the participant and the informing personnel.
: Not applicable.
: PS reports non-financial support from Novartis, personal fees from Boehringer Ingelheim, outside the submitted work. All the other authors declare that they have no competing interests.